MetLife Investment Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.9M | Buy |
140,046
+16,717
| +14% | +$1.2M | 0.05% | 339 |
|
|
2026
Q1 | $8.13M | Buy |
123,329
+1,419
| +1% | +$90.2K | 0.04% | 425 |
|
|
2025
Q4 | $7.75M | Sell |
121,910
-5,680
| -4% | -$353K | 0.04% | 444 |
|
|
2025
Q3 | $7.01M | Sell |
127,590
-4,364
| -3% | -$180K | 0.03% | 482 |
|
|
2025
Q2 | $4.36M | Buy |
131,954
+1,932
| +1% | +$67.2K | 0.03% | 635 |
|
|
2025
Q1 | $5.23M | Sell |
130,022
-3,680
| -3% | -$169K | 0.03% | 588 |
|
|
2024
Q4 | $6.29M | Buy |
133,702
+10,394
| +8% | +$540K | 0.03% | 440 |
|
|
2024
Q3 | $6.51M | Buy |
123,308
+538
| +0.4% | +$30K | 0.04% | 399 |
|
|
2024
Q2 | $6.65M | Buy |
122,770
+22,222
| +22% | +$1.34M | 0.04% | 361 |
|
|
2024
Q1 | $7.05M | Buy |
100,548
+51,460
| +105% | +$3.98M | 0.05% | 336 |
|
|
2023
Q4 | $4.1M | Hold |
49,088
| – | – | 0.03% | 593 |
|
|
2023
Q3 | $1.45M | Hold |
49,088
| – | – | 0.01% | 1048 |
|
|
2023
Q2 | $1.6M | Buy |
49,088
+6,111
| +14% | +$226K | 0.01% | 1026 |
|
|
2023
Q1 | $1.51M | Hold |
42,977
| – | – | 0.01% | 1013 |
|
|
2022
Q4 | $1.97M | Hold |
42,977
| – | – | 0.01% | 906 |
|
|
2022
Q3 | $2.08M | Buy |
42,977
+333
| +0.8% | +$16K | 0.02% | 857 |
|
|
2022
Q2 | $1.68M | Buy |
42,644
+52
| +0.1% | +$2.09K | 0.01% | 961 |
|
|
2022
Q1 | $1.57M | Buy |
42,592
+13,764
| +48% | +$489K | 0.01% | 1094 |
|
|
2021
Q4 | $1.31M | Hold |
28,828
| – | – | 0.01% | 1019 |
|
|
2021
Q3 | $1.03M | Buy |
28,828
+3,351
| +13% | +$98.7K | 0.01% | 1107 |
|
|
2021
Q2 | $504K | Hold |
25,477
| – | – | ﹤0.01% | 1563 |
|
|
2021
Q1 | $593K | Sell |
25,477
-2,978
| -10% | -$63.6K | 0.01% | 1426 |
|
|
2020
Q4 | $591K | Hold |
28,455
| – | – | 0.01% | 1401 |
|
|
2020
Q3 | $616K | Buy |
28,455
+2,107
| +8% | +$49.3K | 0.01% | 1261 |
|
|
2020
Q2 | $621K | Hold |
26,348
| – | – | 0.01% | 1260 |
|
|
2020
Q1 | $311K | Hold |
26,348
| – | – | ﹤0.01% | 1465 |
|
|
2019
Q4 | $280K | Hold |
26,348
| – | – | ﹤0.01% | 1794 |
|
|
2019
Q3 | $300K | Hold |
26,348
| – | – | ﹤0.01% | 1708 |
|
|
2019
Q2 | $296K | Sell |
26,348
-29,800
| -53% | -$287K | ﹤0.01% | 1794 |
|
|
2019
Q1 | $454K | Buy |
56,148
+37,432
| +200% | +$275K | ﹤0.01% | 2109 |
|
|
2018
Q4 | $118K | Hold |
18,716
| – | – | ﹤0.01% | 2213 |
|
|
2018
Q3 | $184K | Hold |
18,716
| – | – | ﹤0.01% | 2135 |
|
|
2018
Q2 | $155K | Hold |
18,716
| – | – | ﹤0.01% | 2032 |
|
|
2018
Q1 | $135K | Hold |
18,716
| – | – | ﹤0.01% | 2084 |
|
|
2017
Q4 | $153K | Buy |
+18,716
| New | +$212K | ﹤0.01% | 2058 |
|
Other funds holding CYTK
ACA
MetLife Investment Management's CYTK Position: Q2 2026 in Review
MetLife Investment Management increased its Cytokinetics (CYTK) stake by 14% in Q2 2026, buying an estimated $1.2M and bringing the position to 140,046 shares worth $11.9M. The position accounts for 0.05% of the portfolio, ranked #339.
MetLife Investment Management first reported a position in CYTK in Q4 2017 and has held it in 35 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- MetLife Investment Management held 140,046 shares of Cytokinetics worth $11.9M as of Q2 2026.
- MetLife Investment Management bought 16,717 Cytokinetics shares in Q2 2026, an estimated $1.2M.
- Cytokinetics made up 0.05% of MetLife Investment Management's portfolio in Q2 2026, its #339 holding.
- MetLife Investment Management first reported a position in Cytokinetics in Q4 2017 and has held it in 35 quarters since.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.